Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc.

Biotech Giants' R&D Spending: A Decade of Innovation

__timestampAlpine Immune Sciences, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 2014121995472242216
Thursday, January 1, 2015160540004536244
Friday, January 1, 2016233160005184803
Sunday, January 1, 2017106260003068742
Monday, January 1, 2018289700007178000
Tuesday, January 1, 20193584700016267000
Wednesday, January 1, 20202718500023191000
Friday, January 1, 20215874200021453000
Saturday, January 1, 20227024300015265000
Sunday, January 1, 20238090400025189000
Loading chart...

In pursuit of knowledge

Innovation in Focus: A Comparative Analysis of R&D Spending

In the ever-evolving landscape of biotechnology, innovation is the lifeblood of progress. Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc. have been at the forefront of this innovation race, as evidenced by their research and development (R&D) spending over the past decade.

From 2014 to 2023, Alpine Immune Sciences has consistently outpaced Soleno Therapeutics in R&D investment. In 2023, Alpine's R&D expenses surged to nearly 3.2 times that of Soleno's, highlighting their commitment to pioneering advancements. Notably, Alpine's R&D spending grew by approximately 563% from 2014 to 2023, reflecting a robust focus on innovation.

Meanwhile, Soleno Therapeutics, despite a more modest R&D budget, has shown a steady increase in investment, with a 1,024% rise over the same period. This underscores their strategic approach to innovation, albeit on a smaller scale.

As these companies continue to prioritize R&D, the biotech industry can anticipate groundbreaking developments that may redefine healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025